Dr. Jack West reviews new findings highlighting the utility of using the biomarker tumor mutation burden (TMB) to predict which patients with small cell lung cancer (SCLC) will benefit from nivolumab or the combination of nivolumab with ipilimumab.
Tumor Mutational Burden in Small Cell Lung Cancer: A Valuable Biomarker for Immunotherapy? (BMIC-011)
